Viking Therapeutics, Inc.

VKTX

US92686J1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-06 pm EST			5-day change	1st Jan Change
50.80 ^USD	+1.84%		-4.04%	+172.97%

Dec. 02	Piper Sandler Initiates Viking Therapeutics at Overweight	MT
Nov. 26	Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Viking Therapeutics, Inc.

Piper Sandler Initiates Viking Therapeutics at Overweight	Dec. 02	MT
Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline	Nov. 26	MT
B. Riley Initiates Viking Therapeutics at Buy With $109 Price Target	Nov. 22	MT
Viking Therapeutics Phase 2b Trial Into Non-Alcoholic Steatohepatitis Meets Primary, Secondary Endpoints	Nov. 19	MT
Viking Therapeutics, Inc. Presents Results from Phase 2b VOYage Study of VOYage Study of Voyage Study of Voyage	Nov. 19	CI
Viking Therapeutics, Inc. Presents at Stifel 2024 Healthcare Conference, Nov-19-2024 08:35 AM	Nov. 19
Social Buzz: Wallstreetbets Stocks Advance Premarket Tuesday; Palantir Technologies, Hims & Hers Health to Open Higher	Nov. 05	MT
Health Care Down as GLP-1 Enthusiasm Wanes -- Health Care Roundup	Nov. 04	DJ
Viking Obesity Data Suggests Pill Can Compete With Shots	Nov. 04	MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $164 From $138, Maintains Outperform Rating	Nov. 04	MT
Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Monday as Investors Focus on Election, Fed Policy Meeting	Nov. 04	MT
Viking Therapeutics Shares Advance Pre-Bell Amid New 'Positive' Data on VK2735 Studies	Nov. 04	MT
Stocks Gain Pre-Bell Ahead of Presidential Elections, Fed Policy Decision; Asia, Europe Rise	Nov. 04	MT
Novo Nordisk share price falls after Viking Therapeutics pill update	Nov. 04	FW
Viking Therapeutics, Inc. Announces Reports New Data from VK2735 Obesity Program at ObesityWeek 2024	Nov. 04	CI
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Viking Therapeutics to Advance, Trump Media & Technology Group to Decline	Nov. 04	MT
Viking Therapeutics Insider Sold Shares Worth $10,089,164, According to a Recent SEC Filing	Oct. 29	MT
Viking Therapeutics to Highlight Clinical Data from VENTURE Phase 2 Study of Subcutaneous Vv2735 in Obese Patients and Phase 1 Trial of Oral Vv2735 in Healthy Subjects to Be Presented	Oct. 28	CI
Viking Therapeutics Insider Sold Shares Worth $1,272,000, According to a Recent SEC Filing	Oct. 28	MT
Sector Update: Health Care Stocks Decline Late Afternoon	Oct. 24	MT
Sector Update: Health Care Stocks Decline Thursday Afternoon	Oct. 24	MT
Viking Therapeutics Shares Rise Following Q3 Results	Oct. 24	MT
Health Care Down After Earnings -- Health Care Roundup	Oct. 23	DJ
Viking Therapeutics Q3 Loss Narrows -- Shares Rise After Hours	Oct. 23	MT
Viking Therapeutics, Inc., Q3 2024 Earnings Call, Oct 23, 2024	Oct. 23

Chart Viking Therapeutics, Inc.

Duration

Period

VKTX: Dynamic Chart

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-02-04 - Q4 2024 Earnings Release (Projected)

More about the company